UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-33624

SINTX Technologies, Inc.

(Exact name of registrant as specified in its charter)

delaware		84-1375299
(State or other jurisdiction		(IRS Employer
of incorporation or organization)		Identification No.)

1885 West 2100 South, Salt Lake City, UT		84119
(Address of principal executive offices)		(Zip Code)

(801) 839-3500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock		SINT		The NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files); Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

24,703,074 shares of common stock, $0.01 par value, were outstanding at August 12, 2021.

SINTX Technologies, Inc.

Table of Contents

Part I. Financial Information
Item 1. Financial Statements
Condensed Consolidated Balance Sheets (unaudited)	3
Condensed Consolidated Statements of Operations (unaudited)	4
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)	5
Condensed Consolidated Statements of Cash Flows (unaudited)	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3. Quantitative and Qualitative Disclosures About Market Risk	23
Item 4. Controls and Procedures	23
Part II. Other Information
Item 1. Legal Proceedings	24
Item 1A. Risk Factors	24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3. Defaults Upon Senior Securities	24
Item 4. Mine Safety Disclosures	24
Item 5. Other Information	24
Item 6. Exhibits	25
Signatures	26

SINTX Technologies, Inc.

Condensed Consolidated Balance Sheets - Unaudited

(in thousands, except share and per share data)

	June 30, 2021			December 31, 2020

Assets
Current assets:
Cash and cash equivalents	$	22,175		$	25,351
Account and other receivables, net of allowance		29			41
Prepaid expenses and other current assets		651			243
Inventories		354			99
Note receivable		-			1,856
Total current assets		23,209			27,590

Inventories		400			388
Property and equipment, net		1,028			471
Intangible assets, net		34			36
Operating lease right of use asset		1,710			1,926
Other long-term assets		35			36
Total assets	$	26,416		$	30,447

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	154		$	194
Accrued liabilities		1,269			909
Current portion of long-term debt		28			109
Derivative liabilities		1,299			1,238
Current portion of operating lease liability		423			403
Other current liabilities		23			26
Total current liabilities		3,196			2,879

Operating lease liability, net of current portion		1,259			1,477
Long term debt, net of current portion		482			287
Total liabilities		4,937			4,643

Commitments and contingencies		-			-

Stockholders’ equity:
Convertible preferred stock Series B, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 26 shares issued and outstanding as of June 30, 2021 and December 31, 2020.		-			-
Convertible preferred stock Series C, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 51 shares issued and outstanding as of June 30, 2021 and December 31, 2020.		-			-
Common stock, $0.01 par value, 250,000,000 shares authorized; 24,700,074 and 24,552,409 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively.		247			245
Additional paid-in capital		267,171			266,666
Accumulated deficit		(245,939	)		(241,107	)
Total stockholders’ equity		21,479			25,804
Total liabilities and stockholders’ equity	$	26,416		$	30,447

The condensed consolidated balance sheet as of December 31, 2020, has been prepared using information from the audited consolidated balance sheet as of that date.

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except share data)

		1			2			3			4
	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Product revenue	$	101		$	204		$	202		$	411
Costs of revenue		73			163			134			329
Gross profit		28			41			68			82
Operating expenses:
Research and development		1,204			1,068			2,799			2,061
General and administrative		858			826			1,858			1,591
Sales and marketing		329			131			615			268
Total operating expenses		2,391			2,025			5,272			3,920
Loss from operations		(2,363	)		(1,984	)		(5,204	)		(3,838	)
Other income (expenses):
Interest expense		(1	)		(1	)		(1	)		(1	)
Interest income		49			85			96			189
Change in fair value of derivative liabilities		(14	)		(2,128	)		(256	)		2,037
Offering costs		-			-			-			(1,246	)
Forgiveness of PPP loan		-			-			391			-
Other income, net		130			-			142			-
Total other income (expense), net		164			(2,044	)		372			979
Net loss before income taxes		(2,199	)		(4,028	)		(4,832	)		(2,859	)
Provision for income taxes		-			-			-			-
Net loss		(2,199	)		(4,028	)		(4,832	)		(2,859	)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock		-			(207	)		-			(9,491	)
Net loss attributable to common stockholders	$	(2,199	)	$	(4,235	)	$	(4,832	)	$	(12,350	)

Net loss per share – basic and diluted
Basic – net loss	$	(0.09	)	$	(0.33	)	$	(0.20	)	$	(0.32	)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock		-			(0.02	)		-			(1.05	)
Basic – attributable to common stockholders	$	(0.09	)	$	(0.35	)	$	(0.20	)	$	(1.37	)

Diluted –net loss	$	(0.09	)	$	(0.33	)	$	(0.20	)	$	(0.45	)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock		-			(0.02	)		-			(0.84	)
Diluted – attributable to common stockholders	$	(0.09	)	$	(0.35	)	$	(0.20	)	$	(1.29	)
Weighted average common shares outstanding:
Basic		24,687,916			12,120,420			24,678,084			9,070,655
Diluted		24,687,916			12,120,420			24,678,084			11,314,252

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Stockholders’ Equity - Unaudited

(in thousands, except share and per share data)

k					1					2				3		4			5			6
	Preferred B Stock					Preferred C Stock					Common Stock				Paid-In			Accumulated			Total
	Shares			Amount		Shares			Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2019		249		$	-		-		$	-		2,434,009	$	24	$	239,256		$	(234,078	)	$	5,202
Stock based compensation
Common stock issued for cash
Common stock issued for cash, shares
Extinguishment of derivative liability upon exercise of warrant		-			-		-			-		3,128,895		32		1,525			-			1,557
Issuance of common stock from the exercise of warrants for cash		-			-		-			-		100		-		-			-			-
Issuance of common stock from the cashless exercise of warrants
Issuance of common stock from the cashless exercise of warrants, shares
Preferred stock issued for cash		-			-		9,440			-		-		-		3,112			-			3,112
Common stock issued on conversion of preferred stock		-			-		(9,208	)		-		6,215,742		62		(62	)		-			-
Issuance of agent warrants		-			-		-			-		-		-		168			-			168
Beneficial conversion feature on issuance of convertible preferred stock		-			-		-			-		-		-		3,111			-			3,111
Deemed dividend related to the issuance of preferred stock		-			-		-			-		-		-		(3,111	)		-			(3,111	)
Accretion of convertible preferred stock discount		-			-		-			-		-		-		6,173			-			6,173
Deemed dividend related to the conversion of preferred stock		-			-		-			-		-		-		(6,173	)		-			(6,173	)
Net income		-			-		-			-		-		-		-			1,169			1,169
Balance as of March 31, 2020		249			-		232			-		11,778,746		118	$	243,999			(232,909	)		11,208
Common stock issued for cash		-			-		-			-		6,454,381		65		9,583			-			9,648
Extinguishment of derivative liability upon exercise of warrant		-			-		-			-		-		-		1,451			-			1,451
Issuance of common stock from the exercise of warrants for cash		-			-		-			-		611,868		6		911			-			917
Issuance of common stock from the cashless exercise of warrants		-			-		-			-		373,750		3		(3	)		-			-
Common stock issued for conversion of preferred stock		(123	)		-		(179	)		-		212,168		2		(2	)		-			-
Common stock issued on conversion of preferred stock		(123	)		-		(179	)		-		212,168		2		(2	)		-			-
Accretion of convertible preferred stock discount		-			-		-			-		-		-		207			-			207
Deemed dividend related to the conversion of preferred stock		-			-		-			-		-		-		(207	)		-			(207	)
Net income		-			-		-			-		-		-		-			(4,028	)		(4,028	)
Balance as of June 30, 2020		126		$	-		53		$	-		19,430,913	$	194	$	255,939		$	(236,937	)	$	19,196

	Preferred B Stock				Preferred C Stock				Common Stock				Paid-In		Accumulated			Total
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance as of December 31, 2020		26	$	-		51	$	-		24,552,409	$	245	$	266,666	$	(241,107	)	$	25,804
Stock based compensation		-		-		-		-		-		-		36		-			36
Extinguishment of derivative liability upon exercise of warrant		-		-		-		-		-		-		195		-			195
Issuance of common stock upon exercise of warrants for cash		-		-		-		-		130,275		2		194		-			196
Issuance of common stock from the cashless exercise of warrants		-		-		-		-		1,890		-		-		-			-
Net loss		-		-		-		-		-		-		-		(2,633	)		(2,633	)
Balance as of March 31, 2021		26		-		51		-		24,684,574		247		267,091		(243,740	)		23,598
Stock based compensation		-		-		-		-		15,500		-		80		-			80
Net loss		-		-		-		-		-		-		-		(2,199	)		(2,199	)
Net income (loss)		-		-		-		-		-		-		-		(2,199	)		(2,199	)
Balance as of June 30, 2021		26	$	-		51	$	-		24,700,074	$	247	$	267,171	$	(245,939	)	$	21,479

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Cash Flows - Unaudited

(in thousands)

		1			2
	Six Months Ended June 30,
	2021			2020
Cash Flow From Operating Activities
Net loss	$	(4,832	)	$	(2,859	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation expense		70			34
Amortization of right of use asset		215			206
Amortization of intangible assets		2			2
Non-cash interest income		(88	)		(172	)
Stock based compensation		116			-
Change in fair value of derivative liabilities		256			(2,037	)
Offering costs		-			325
Gain on disposal of equipment		(144	)		-
Forgiveness of PPP loan		(391	)		-
Changes in operating assets and liabilities:
Trade accounts receivable		12			76
Prepaid expenses and other current assets		(408	)		(251	)
Inventories		(267	)		(20	)
Accounts payable and accrued liabilities		318			(79	)
Payments on operating lease liability		(198	)		(163	)
Net cash used in operating activities		(5,339	)		(4,938	)
Cash Flows From Investing Activities
Purchase of property and equipment		(626	)		(77	)
Proceeds from notes receivable, net of imputed interest		1,944			944
Proceeds from sale of property and equipment		144			-
Net cash provided by investing activities		1,462			867
Cash Flows From Financing Activities
Proceeds from issuance of preferred stock		-			3,112
Proceeds from issuance of warrant derivative liabilities		-			6,328
Proceeds from issuance of common stock, net of fees		-			9,648
Proceeds from issuance of common stock in connection with exercise of warrants		196			917
Proceeds from issuance of debt		510			406
Payments on debt		(5	)		(2	)
Net cash provided by financing activities		701			20,409
Net increase (decrease) in cash and cash equivalents		(3,176	)		16,338
Cash and cash equivalents at beginning of period		25,351			1,787
Cash and cash equivalents at end of period	$	22,175		$	18,125

Noncash Investing and Financing Activities
Extinguishment of derivative liabilities through exercise of warrants	$	195		$	3,008
Change in par value due to conversion of preferred stock to common stock		-			64
Issuance of common stock for the cashless exercise of warrants		-			35
Supplemental Cash Flow Information
Cash paid for interest	$	-		$	1

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Summary of Significant Accounting Policies

Organization

SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996 (and was previously known as Amedica Corporation). SINTX is an OEM ceramics company that develops and commercializes silicon nitride and other ceramics for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics and other ceramics for its own account as well as for external partners. The Company presently manufactures silicon nitride spinal implants in its ISO 13485:2016 certified manufacturing facility for CTL Amedica, the exclusive retail channel for silicon nitride spinal implants. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. In July 2021, the Company acquired the equipment and certain intellectual property rights with which it intends to develop, manufacture and commercialize protective armor plates from boron carbide and a composite material of silicon carbide and boron carbide for military, law enforcement and civilian uses (see Note 13). The Company’s products are primarily sold in the United States.

On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical, a Dallas, Texas-based privately held medical device manufacturer. As a result of the sale, CTL Medical became the exclusive owner of the Company’s portfolio of metal and silicon nitride spine products, and has access to future silicon nitride spine technologies developed by the Company. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company. The Company serves as CTL’s exclusive OEM provider of silicon nitride products.

On October 30, 2018, the Company amended its Certificate of Incorporation with the State of Delaware to change its corporate name to SINTX Technologies, Inc. in order to better reflect its focus on silicon nitride science and technologies and pipeline of silicon nitride-based products in various biomedical applications. The Company also changed its trading symbol on the NASDAQ Capital Market to “SINT”.

The previous name, Amedica, was transferred to CTL Medical, which is now CTL Amedica. The Company’s new corporate brand reflects both the Company’s core competence in the science and production of silicon nitride ceramics and other ceramics, as well as encouraging prospects for the future, as an OEM supplier of spine implants to CTL Amedica, and multiple opportunities outside of spine. As SINTX Technologies Inc., the Company is focusing on developing silicon nitride in terms of product design, and future biomaterial formulations, for a variety of OEM customers and other ceramics for its own account.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. In May 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution, the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated.

SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 22, 2021. The results of operations for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2020.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of June 30, 2021, the most significant estimate relates to derivative liabilities relating to common stock warrants.

Liquidity and Capital Resources

The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.

For the six months ended June 30, 2021 and 2020, the Company incurred a net loss of $2.2 million and $4.0 million, respectively, and used cash in operations of $5.3 million and $4.9 million, respectively. The Company had an accumulated deficit of $245.9 million and $241.1 million as of June 30, 2021 and December 31, 2020, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.

The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications. The Company has also acquired equipment and certain intellectual property rights for the purpose of developing, manufacturing and commercializing armored plates made from boron carbide and a composite of boron carbide and silicon carbide for military, law enforcement and other civilian uses.

The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during the period of June 2020 through August 2020, the Company closed four registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 11,015,000 shares of its common stock for gross proceeds of approximately $20.9 million, before considering issuance costs of approximately $1.6 million (see Note 8).

During the year ended December 31, 2019, the Company entered into an at-the-market (2019 ATM) equity distribution agreement under which the Company could sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. During the year ended December 31, 2020, the Company sold 354,381 shares of common stock under the ATM, raising approximately $0.8 million before deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of June 30, 2021, no funding capacity is available under the ATM. (see Note 8).

On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Distribution Agreement”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of the Company’s common stock having an aggregate offering price of up to $15.0 million through Maxim, as agent. As of June 30, 2021, there have been no sales of shares of common stock under the 2021 Distribution Agreement.

Management has concluded existing capital resources will be sufficient to fund operations for at least the next 12 months, or through August 2022.

Risks Related to COVID-19 Pandemic

The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. In response to the spread of COVID-19 and to ensure safety of employees and continuity of business operations, we temporarily restricted access to the facility, with our administrative employees continuing their work remotely and limited the number of staff in our manufacturing facility. We implemented protective measures such as wearing of face masks, maintaining social distancing, and additional cleaning. Beginning in 2021, we have offered vaccination incentives. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.

New Accounting Pronouncements Not Yet Adopted

The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

2. Basic and Diluted Net Income (Loss) per Common Share

Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. For the three months ended June 30, 2021, there is no difference in the number of shares and net loss used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive. The Company had potentially dilutive securities, totaling approximately 1.8 million and 1.3 million as of June 30, 2021 and 2020, respectively.

Below are basic and diluted loss per share data for the three months ended June 30, 2021, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(2,199	)	$	-	$	(2,199	)
Deemed dividend and accretion of a discount		-			-		-
Net loss attributable to common stockholders	$	(2,199	)	$	-	$	(2,199	)

Denominator:
Number of shares used in per common share calculations:		24,687,916			-		24,687,916

Net loss per common share:
Net loss	$	(0.09	)	$	-	$	(0.09	)
Deemed dividend and accretion of a discount		-			-		-
Net loss attributable to common stockholders	$	(0.09	)	$	-	$	(0.09	)

Below are basic and diluted loss per share data for the six months ended June 30, 2021, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(4,832	)	$	-	$	(4,832	)
Deemed dividend and accretion of a discount		-			-		-
Net loss attributable to common stockholders	$	(4,832	)	$	-	$	(4,832	)

Denominator:
Number of shares used in per common share calculations:		24,678,084			-		24,678,084

Net loss per common share:
Net loss	$	(0.20	)	$	-	$	(0.20	)
Deemed dividend and accretion of a discount		-			-		-
Net loss attributable to common stockholders	$	(0.20	)	$	-	$	(0.20	)

Below are basic and diluted loss per share data for the three months ended June 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(4,028	)	$	-	$	(4,028	)
Deemed dividend and accretion of a discount		(207	)		-		(207	)
Net loss attributable to common stockholders	$	(4,235	)	$	-	$	(4,235	)

Denominator:
Number of shares used in per common share calculations:		12,120,420			-		12,120,420

Net loss per common share:
Net loss	$	(0.33	)	$	-	$	(0.33	)
Deemed dividend and accretion of a discount		(0.02	)		-		(0.02	)
Net loss attributable to common stockholders	$	(0.35	)	$	-	$	(0.35	)

Below are basic and diluted loss per share data for the six months ended June 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(2,859	)	$	(2,191	)	$	(5,050	)
Deemed dividend and accretion of a discount		(9,491	)		-			(9,491
Net loss attributable to common stockholders	$	(12,350	)

SEC Form 10-Q filed by SiNtx Technologies, Inc.